Central nervous system lymphoma is a rare disease. Therapeutic approaches require a fine balance between destroying all tumor cells while sparing surrounding healthy brain tissue. Circulating tumor DNA sequencing is a noninvasive method offering significant advantages regarding feasibility and repeatability as compared to invasive brain biopsies. However, the role of the blood-brain-barrier in releasing circulating tumor DNA into the peripheral blood and being permeable to drugs remains elusive. This project aims at elucidating the role of the blood-brain-barrier in central nervous system lymphoma to further improve methods for individualized risk stratification.

Here you can find further information.